Despite substantial progress in the development of chemotherapy in combination with trastuzumab (IgG1 monoclonal antibody targeting the human epidermal growth factor receptor 2 [HER2]), which has been demonstrated to result in an improved survival rate of patients with positive HER2 expression, the current treatment options for advanced GC patients are limited [8]. Here, ERBB2 is linked to gastric cancer.